HBM HOLDINGS-B (02142) announced that its indirect wholly-owned subsidiary, HBM (Shanghai) Co., Ltd., has amended its collaboration, option, and license agreement with AstraZeneca PLC. The revised agreement, effective November 24, 2025, expands the scope of cooperation between the two parties. The enhanced partnership aims to leverage the combined expertise of both companies to jointly discover and develop next-generation biologic therapies, including antibody-drug conjugates (ADCs) and T-cell engagers. The financial terms remain consistent with the framework established under the original agreement.